Does Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate Interact with Atazanavir?
CDI records a contraindicated classification for Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and Atazanavir. The stored summary is: Coadministration is not recommended. Decreases atazanavir concentrations while increasing tenofovir concentrations. The mechanism involves efavirenz induction of cyp3a and decreased atazanavir plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Efavirenz induction of CYP3A and decreased atazanavir plasma concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Atazanavir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider